The U.S. Trustee, the bankruptcy arm of the Justice Department, will appoint one or more committees to represent the interests of creditors and stockholders in working with the company to develop a plan of reorganization to get out of debt.
Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH).
The discounted price, though, is kept secret at the companyâs request. Soliris has also been approved to treat atypical hemolytic uremic syndrome (aHUS), a genetic disorder believed to affect 60-90 Canadians, causing dangerous blood clots. The annual treatment cost is $700,000, according to the PMPRB.